Company Description
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs.
It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).
The company also develops EMPAVELI to treat C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, hematopoietic stem cell transplantation-associated thrombotic microangiopathy, focal segmental glomerulosclerosis, and delayed graft function; and APL-3007, a small interfering RNA, or siRNA for the treatment of GA.
It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) for development and commercialization of pegcetacoplan; and a collaboration with Beam Therapeutics Inc. focused on the use of Beam’s base editing technology to discover new treatments for complement-driven diseases.
The company was incorporated in 2009 and is based in Waltham, Massachusetts.
| Country | United States |
| Founded | 2009 |
| IPO Date | Nov 9, 2017 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 710 |
| CEO | Cedric Francois |
Contact Details
Address: 100 Fifth Avenue Waltham, Massachusetts 02451 United States | |
| Phone | 617 977 5700 |
| Website | apellis.com |
Stock Details
| Ticker Symbol | APLS |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001492422 |
| CUSIP Number | 03753U106 |
| ISIN Number | US03753U1060 |
| Employer ID | 27-1537290 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Cedric Francois M.D., Ph.D. | Co-Founder, President, Chief Executive Officer and Director |
| Alec Machiels J.D., MBA | Co-Founder and Director |
| Timothy E. Sullivan | Chief Financial Officer and Treasurer |
| David O. Watson Esq., J.D. | General Counsel |
| Dr. Caroline R. Baumal M.D. | Chief Medical Officer |
| Dr. Pascal Deschatelets Ph.D. | Co-Founder and Chief Scientific Officer |
| James G. Chopas CPA | Vice President, Corporate Controller and Chief Accounting Officer |
| Meredith Kaya | Senior Vice President, Investor Relations and Strategic Finance |
| Prof. Peter Hillmen M.D., Ph.D. | Head of Hematology Engagement and Member of PNH Scientific Advisory Board |
| Victoria L. Brown | Senior Vice President |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 23, 2025 | ARS | Filing |
| Apr 23, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 23, 2025 | DEF 14A | Other definitive proxy statements |
| Apr 21, 2025 | 8-K | Current Report |
| Mar 17, 2025 | 144 | Filing |
| Mar 5, 2025 | 144 | Filing |
| Feb 28, 2025 | S-8 | Securities to be offered to employees in employee benefit plans |
| Feb 28, 2025 | 10-K | Annual Report |
| Feb 11, 2025 | 144 | Filing |
| Feb 10, 2025 | SCHEDULE 13G/A | Filing |